FDA pushes back review deadline for Theratechnologies' tesamorelin

02/25/2010 | Reuters

The FDA postponed its deadline for reviewing Theratechnologies' drug tesamorelin to July 27 after a panel meeting was moved to May 27. The drugmaker submitted tesamorelin for approval to treat excess abdominal fat in HIV-positive patients.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD